Title |
New treatment strategies for HPV-positive head and neck cancer
|
---|---|
Published in |
European Archives of Oto-Rhino-Laryngology, August 2013
|
DOI | 10.1007/s00405-013-2603-0 |
Pubmed ID | |
Authors |
B. Kofler, S. Laban, C. J. Busch, B. Lörincz, R. Knecht |
Abstract |
Epidemiological studies show an increasing incidence of human papilloma virus-associated oropharyngeal cancer. HPV-positive head and neck squamous cell carcinoma (HNSCC) is recognized as a special subgroup of HNSCC. Because HPV-positive patients are often younger and have an outstanding prognosis, long-term toxicities of therapy have become an important issue. Current clinical trials focus on a reduction of treatment-related toxicity and the development of HPV-specific therapies. New treatment strategies include a dose reduction of radiotherapy, the use of cetuximab instead of cisplatin for chemoradiation and transoral robotic surgery (TORS). Increasing comprehension of the molecular background of HPV-associated HNSCC has also lead to more specific treatment attempts including immunotherapeutic strategies. Whereas recently published data shed light on immune mechanisms resulting in a tolerogenic niche for HPV and HPV-associated HNSCC, other studies focus on specific vaccination of HPV-positive HNSCC. This study will summarize current therapy approaches and illustrate ongoing clinical trials in the field of HPV-positive HNSCC. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Ecuador | 1 | <1% |
France | 1 | <1% |
Canada | 1 | <1% |
Unknown | 98 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 17 | 17% |
Student > Bachelor | 14 | 14% |
Researcher | 10 | 10% |
Student > Ph. D. Student | 10 | 10% |
Other | 9 | 9% |
Other | 24 | 24% |
Unknown | 18 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 43% |
Biochemistry, Genetics and Molecular Biology | 13 | 13% |
Agricultural and Biological Sciences | 10 | 10% |
Nursing and Health Professions | 2 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Other | 5 | 5% |
Unknown | 26 | 25% |